←Back to Expert Scholars
Translational Medicine / 转化医学Checkpoint Combinations, Early Phase Trials
Aung Naing
MD
🏢MD Anderson Cancer Center🌐USA
Professor of Investigational Cancer Therapeutics
55
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Aung Naing leads early-phase immunotherapy trials at MD Anderson including studies of pegilodecakin and other novel cytokine agents combined with checkpoint inhibitors. He has advanced immunotherapy for rare tumors. His work focuses on novel combinatorial strategies with checkpoint blockade.
Share:
🧪Research Fields 研究领域
early phase trials
IL-10 agonists
PEGylated cytokines
checkpoint combinations
rare tumor immunotherapy
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Aung Naing 的研究动态
Follow Aung Naing's research updates
留下邮箱，当我们发布与 Aung Naing（MD Anderson Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment